Intelligent anti-aging skin care based on independent research     
Lose wrinkles, keep your bank account!     
 
Skin Care 101
Skin Care Basics
Skin Protection
Skin Biology
Biology of Aging
Ingredient Guide
Skin & Nutrition
Skin Conditions
 
Anti-Aging Treatments
Topical Actives
Wrinkle Fillers
Noninvasive
Invasive
 
Skin Care Smarts
Smart Choices
Best Practices
Find Good Skin Doc
Quick Tips
Freebie Finder
 
Reviews & Research
Product Reviews
Provider Reviews
Skin Care Research
Clinical Trials
 
How-To Infopacks
Skin Rejuvenation
DIY Skin Care
Skin & Nutrition
Eye Skin Care
Longevity In a Pill
 
Community & Misc
Forums
Polls & Surveys
News and Updates
Search
 
   
You are here: Skin Care Research >

Once-daily tazarotene 0.1 % gel versus once-daily tretinoin 0.1 % microsponge gel for the treatment of facial acne vulgaris: a double-blind randomized trial

Author: Leyden JJ; Tanghetti EA; Miller B; Ung M; Berson D; Lee J

Author affiliation: University of Pennsylvania Hospital, Philadelphia, USA.

Publication date & source: 2002.02, Cutis, 69(2 Suppl):12-9

Publication type: clinical trial

The efficacy and tolerability of tazarotene 0.1% gel and tretinoin 0.1% microsponge gel were evaluated in a multicenter, double-blind, randomized, parallel-group study in patients with mild-to-moderate inflammatory facial acne vulgaris. A total of 169 patients were randomized to once-daily applications of one of these topical retinoids for 12 weeks. Both agents were associated with significant reductions from baseline in the noninflammatory and inflammatory lesion counts. Tazarotene treatment was associated with a significantly greater incidence of treatment success (defined as > or = 50% global improvement [67% vs 49%; P=.03]) and significantly greater reductions in overall disease severity (36% vs 26%; P=.02) and noninflammatory lesion count (60% vs 38% at week 12; P=.02) than tretinoin microsponge treatment. Both drugs were well tolerated, with mean levels of dryness, burning, pruritus, erythema, and peeling generally being no more than trace throughout the study. There were no clinically significant between-group differences in these measures of tolerability. Two patients in each group (2%) discontinued because of treatment-related adverse events. The mean amount of medication applied by the patients was 0.28 g per application with tazarotene and 0.41 g per application with tretinoin microsponge, resulting in cost-effectiveness ratios of $81.45 per treatment success with tazarotene and $108.24 per treatment success with tretinoin microsponge. Tazarotene was observed to have greater efficacy and comparable tolerability and to be a cost-effective alternative to tretinoin 0.1% microsponge gel.



Indexes of Skin Care Research Abstracts
by Subject Category Most Recent


Google
 
Web SmartSkinCare.com

Home | About Us | Contact Us | Ask a Question | Resources

Copyright © 1999-2010 by Dr. G. Todorov / SmartSkinCare.com
Site Disclaimer | Copyright Certification

   
-- advertisements --